An increase in Development and Launch of New Drugs will Bolster the Growth of the Global Bipolar Disorder Drugs Market

The global bipolar disorder drugs market is anticipated to grow at a considerable CAGR of during the forecast period (2022-2028). Several major players operating within the bipolar disorder drugs market are inclined towards the adoption of various strategic alliances such as acquisitions, partnerships, collaborations, and the launching of new drugs and vaccines to provide advanced treatment for bipolar disorder treatment globally. This is the primary and major factor that is supporting the growth of the market.

Browse the full report of " Global Bipolar disorder Drug Market Size, Share & Trends Analysis Report by Drug Type (Mood Stabilizers, Anti-Psychotic Drug, Anti–Depressant Drug, and Anti-Anxiety Drug), and by Distribution Channel (Online Pharmacy and Offline Pharmacy) Forecast (2022-2028)" at https://www.omrglobal.com/industry-reports/bipolar-disorder-drugs-market

For instance, In June 2021, USFDA approved a new drug option to treat patients with schizophrenia and bipolar disorder I which is a combination of olanzapine and semi orphan and can be taken once daily. Several other drugs are in the pipeline which will be a combination of old drugs with new drug type that are intended for the treatment of bipolar disorder more effectively. Further, in March 2019, VistaGen Therapeutics, a biopharmaceutical company developed a new general medicine to treat various bipolar disorders including depression, social anxiety disorder, and central nervous system disease. in March 2019, the US Food and Drug Administration (USFDA) approved Johnson & Johnson Healthcare nasal spray antidepressant for people resistant to other treatments. The drug esketamine nasal spray works within an hour.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Drug type
• By Distribution channel

Regions Covered- 

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape - Allergan, AstraZeneca, Eli Lilly and Co., GlaxoSmithKline, Pfizer Inc., and others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Bipolar disorder drugs Market Report Segment

By Drug Type

• Mood Stabilizers
• Anti-Depressant Drug 
• Anti-Psychotic Drug
• Anti-Anxiety Drug

By Distribution Channel

• Online Pharmacies
• Offline Pharmacies

Global Bipolar disorder drugs Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa